PR Newswire UK Disclose - LILLY (ELI) & COMPANY - Lilly Announces Updates:Zyprexa and Symbyax U.S. Labels.

Date: October 5, 2007

For Release: Immediately
Refer to: (317) 433-8990 - Marni Lemons, (317) 532-7826 - mobile

(317) 276-3787 - Tarra Ryker, (317) 332-7502 - mobile

Lilly Announces Updates to the Zyprexa and Symbyax U.S. Labels

Indianapolis, IN - Eli Lilly and Company announced today that as a part of
ongoing discussions with the U.S.

Related Results

Antipsychotic-associated weight gain.(EVIDENCE-BASED PSYCHIATRIC MEDICINE)

FDA Issues Not-Approvable Letter for Lilly’s Zyprexa Long-Acting Inject…

Lilly and schering offer modest 4Q results. (News).(Brief Article)

Indianapolis-Based Eli Lilly Warns of Drug Tampering.

Testimony Regarding Eli Lilly Drug’s Patent-Worthiness Turns to Hormone Levels.

Food and Drug Administration (FDA), the company has
updated the ZyprexaA[R] (olanzapine) and SymbyaxA[R] (olanzapine and fluoxetine HCl)
U.S. product labels. This new labeling information is available at
www.Zyprexa.com and www.Symbyax.com.

Read the rest of this article with a Free Trial at HighBeam Research.